Interindividual variability in genes encoding drug-metabolizing enzymes, transporters,
receptors, and human leukocyte antigens has a major impact on a patient's response to …

Pharmacogenomics is the examination of how genetic variation influences drug metabolism
and response, in terms of both efficacy and safety. In cardiovascular disease, patient …

Low drug adherence is a major obstacle to the benefits of pharmacotherapies and it is
therefore important to identify factors associated with discontinuing or being poorly adherent …

Genomic prediction of antipsychotic dose and polypharmacy has been difficult, mainly due
to limited access to large cohorts with genetic and drug prescription data. In this proof of …

Large biobanks have set a new standard for research and innovation in human genomics
and implementation of personalised medicine. The Estonian Biobank was founded a quarter …

A recent population-based cohort study found an association between proton pump inhibitor
(PPI) prescription and risk of inflammatory bowel disease which they attributed to protopathic …

Furin is an important proteolytic enzyme, converting several proteins from inactive
precursors to their active forms. Recently, proteo-genomic analyses in European and East …

Insulin resistance is a major indicator of cardiovascular diseases, including hypertension.
The Metabolic Score for Insulin Resistance (METS-IR) offers a simplified and cost-effective …

Electronic health records (EHRs) coupled with large-scale biobanks offer great promises to
unravel the genetic underpinnings of treatment efficacy. However, medication-induced …

Low drug adherence is a major obstacle to the benefits of pharmacotherapies and it is
therefore important to identify factors associated with discontinuing or being poorly adherent …